Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting

Kenichi Takayasu, Shigeki Arii, Michiie Sakamoto, Yutaka Matsuyama, Masatoshi Kudo, Shuichi Kaneko, Osamu Nakashima, Masumi Kadoya, Namiki Izumi, Tadatoshi Takayama, Yonson Ku, Takashi Kumada, Shoji Kubo, Takashi Kokudo, Yasuhiro Hagiwara, Norihiro Kokudo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Aims: Small hypovascular hepatocellular carcinoma (HCC) ≤2 cm is biologically less aggressive than hypervascular one, however, the optimal treatment is still undetermined. The efficacy of surgical resection (SR), radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) was evaluated. Methods: The 853 (SR, 176; RFA, 491; PEI, 186) patients were enrolled who met Child-Pugh A/B, single hypovascular HCC ≤2 cm pathologically proven, available tumour differentiation and absence of macrovascular invasion and extrahepatic metastasis. Overall and recurrence-free survivals were compared in original and a propensity score weighted pseudo-population with 732 patients. Results: The median follow-up time and tumour size were 2.8 years and 1.47 cm respectively. In original population, multivariate Cox regression showed no significant difference for overall survival among three groups. In pseudo-population, Cox regression also revealed no significant difference for overall survival among them, although SR (HR, 0.56; 95% CI, 0.36-0.86) and RFA (HR, 0.75; 95% CI, 0.57-1.00) groups had significantly lower recurrence than PEI group. The overall survival rates at 3 and 5 years for the SR, RFA and PEI groups were 94%/70%, 90%/75% and 94%/73% respectively. Corresponding recurrence-free survival rates were 64%/54%, 59%/41% 48%/33% respectively. Subgroup analysis revealed no significant survival benefit of SR compared with non-SR. No treatment-related death occurred. Conclusions: For patients with single hypovascular HCC ≤2 cm, no significant difference for overall survival was first identified among 3 treatment groups. The SR or RFA could be recommended, and PEI would be alternative to RFA.

Original languageEnglish
JournalLiver International
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Propensity Score
Hepatocellular Carcinoma
Ethanol
Injections
Survival
Recurrence
Survival Rate
Population
Neoplasms
Therapeutics
Neoplasm Metastasis

Keywords

  • Barcelona clinic liver cancer stage 0
  • Hypovascular hepatocellular carcinoma
  • Injection
  • Inverse-probability-of-treatment weighting
  • Percutaneous ethanol
  • Radiofrequency ablation
  • Surgical resection

ASJC Scopus subject areas

  • Hepatology

Cite this

Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. / Takayasu, Kenichi; Arii, Shigeki; Sakamoto, Michiie; Matsuyama, Yutaka; Kudo, Masatoshi; Kaneko, Shuichi; Nakashima, Osamu; Kadoya, Masumi; Izumi, Namiki; Takayama, Tadatoshi; Ku, Yonson; Kumada, Takashi; Kubo, Shoji; Kokudo, Takashi; Hagiwara, Yasuhiro; Kokudo, Norihiro.

In: Liver International, 01.01.2018.

Research output: Contribution to journalArticle

Takayasu, K, Arii, S, Sakamoto, M, Matsuyama, Y, Kudo, M, Kaneko, S, Nakashima, O, Kadoya, M, Izumi, N, Takayama, T, Ku, Y, Kumada, T, Kubo, S, Kokudo, T, Hagiwara, Y & Kokudo, N 2018, 'Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting', Liver International. https://doi.org/10.1111/liv.13670
Takayasu, Kenichi ; Arii, Shigeki ; Sakamoto, Michiie ; Matsuyama, Yutaka ; Kudo, Masatoshi ; Kaneko, Shuichi ; Nakashima, Osamu ; Kadoya, Masumi ; Izumi, Namiki ; Takayama, Tadatoshi ; Ku, Yonson ; Kumada, Takashi ; Kubo, Shoji ; Kokudo, Takashi ; Hagiwara, Yasuhiro ; Kokudo, Norihiro. / Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. In: Liver International. 2018.
@article{1386f4c3f503436c86cabfb65ac68bb8,
title = "Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting",
abstract = "Background and Aims: Small hypovascular hepatocellular carcinoma (HCC) ≤2 cm is biologically less aggressive than hypervascular one, however, the optimal treatment is still undetermined. The efficacy of surgical resection (SR), radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) was evaluated. Methods: The 853 (SR, 176; RFA, 491; PEI, 186) patients were enrolled who met Child-Pugh A/B, single hypovascular HCC ≤2 cm pathologically proven, available tumour differentiation and absence of macrovascular invasion and extrahepatic metastasis. Overall and recurrence-free survivals were compared in original and a propensity score weighted pseudo-population with 732 patients. Results: The median follow-up time and tumour size were 2.8 years and 1.47 cm respectively. In original population, multivariate Cox regression showed no significant difference for overall survival among three groups. In pseudo-population, Cox regression also revealed no significant difference for overall survival among them, although SR (HR, 0.56; 95{\%} CI, 0.36-0.86) and RFA (HR, 0.75; 95{\%} CI, 0.57-1.00) groups had significantly lower recurrence than PEI group. The overall survival rates at 3 and 5 years for the SR, RFA and PEI groups were 94{\%}/70{\%}, 90{\%}/75{\%} and 94{\%}/73{\%} respectively. Corresponding recurrence-free survival rates were 64{\%}/54{\%}, 59{\%}/41{\%} 48{\%}/33{\%} respectively. Subgroup analysis revealed no significant survival benefit of SR compared with non-SR. No treatment-related death occurred. Conclusions: For patients with single hypovascular HCC ≤2 cm, no significant difference for overall survival was first identified among 3 treatment groups. The SR or RFA could be recommended, and PEI would be alternative to RFA.",
keywords = "Barcelona clinic liver cancer stage 0, Hypovascular hepatocellular carcinoma, Injection, Inverse-probability-of-treatment weighting, Percutaneous ethanol, Radiofrequency ablation, Surgical resection",
author = "Kenichi Takayasu and Shigeki Arii and Michiie Sakamoto and Yutaka Matsuyama and Masatoshi Kudo and Shuichi Kaneko and Osamu Nakashima and Masumi Kadoya and Namiki Izumi and Tadatoshi Takayama and Yonson Ku and Takashi Kumada and Shoji Kubo and Takashi Kokudo and Yasuhiro Hagiwara and Norihiro Kokudo",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/liv.13670",
language = "English",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting

AU - Takayasu, Kenichi

AU - Arii, Shigeki

AU - Sakamoto, Michiie

AU - Matsuyama, Yutaka

AU - Kudo, Masatoshi

AU - Kaneko, Shuichi

AU - Nakashima, Osamu

AU - Kadoya, Masumi

AU - Izumi, Namiki

AU - Takayama, Tadatoshi

AU - Ku, Yonson

AU - Kumada, Takashi

AU - Kubo, Shoji

AU - Kokudo, Takashi

AU - Hagiwara, Yasuhiro

AU - Kokudo, Norihiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Aims: Small hypovascular hepatocellular carcinoma (HCC) ≤2 cm is biologically less aggressive than hypervascular one, however, the optimal treatment is still undetermined. The efficacy of surgical resection (SR), radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) was evaluated. Methods: The 853 (SR, 176; RFA, 491; PEI, 186) patients were enrolled who met Child-Pugh A/B, single hypovascular HCC ≤2 cm pathologically proven, available tumour differentiation and absence of macrovascular invasion and extrahepatic metastasis. Overall and recurrence-free survivals were compared in original and a propensity score weighted pseudo-population with 732 patients. Results: The median follow-up time and tumour size were 2.8 years and 1.47 cm respectively. In original population, multivariate Cox regression showed no significant difference for overall survival among three groups. In pseudo-population, Cox regression also revealed no significant difference for overall survival among them, although SR (HR, 0.56; 95% CI, 0.36-0.86) and RFA (HR, 0.75; 95% CI, 0.57-1.00) groups had significantly lower recurrence than PEI group. The overall survival rates at 3 and 5 years for the SR, RFA and PEI groups were 94%/70%, 90%/75% and 94%/73% respectively. Corresponding recurrence-free survival rates were 64%/54%, 59%/41% 48%/33% respectively. Subgroup analysis revealed no significant survival benefit of SR compared with non-SR. No treatment-related death occurred. Conclusions: For patients with single hypovascular HCC ≤2 cm, no significant difference for overall survival was first identified among 3 treatment groups. The SR or RFA could be recommended, and PEI would be alternative to RFA.

AB - Background and Aims: Small hypovascular hepatocellular carcinoma (HCC) ≤2 cm is biologically less aggressive than hypervascular one, however, the optimal treatment is still undetermined. The efficacy of surgical resection (SR), radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) was evaluated. Methods: The 853 (SR, 176; RFA, 491; PEI, 186) patients were enrolled who met Child-Pugh A/B, single hypovascular HCC ≤2 cm pathologically proven, available tumour differentiation and absence of macrovascular invasion and extrahepatic metastasis. Overall and recurrence-free survivals were compared in original and a propensity score weighted pseudo-population with 732 patients. Results: The median follow-up time and tumour size were 2.8 years and 1.47 cm respectively. In original population, multivariate Cox regression showed no significant difference for overall survival among three groups. In pseudo-population, Cox regression also revealed no significant difference for overall survival among them, although SR (HR, 0.56; 95% CI, 0.36-0.86) and RFA (HR, 0.75; 95% CI, 0.57-1.00) groups had significantly lower recurrence than PEI group. The overall survival rates at 3 and 5 years for the SR, RFA and PEI groups were 94%/70%, 90%/75% and 94%/73% respectively. Corresponding recurrence-free survival rates were 64%/54%, 59%/41% 48%/33% respectively. Subgroup analysis revealed no significant survival benefit of SR compared with non-SR. No treatment-related death occurred. Conclusions: For patients with single hypovascular HCC ≤2 cm, no significant difference for overall survival was first identified among 3 treatment groups. The SR or RFA could be recommended, and PEI would be alternative to RFA.

KW - Barcelona clinic liver cancer stage 0

KW - Hypovascular hepatocellular carcinoma

KW - Injection

KW - Inverse-probability-of-treatment weighting

KW - Percutaneous ethanol

KW - Radiofrequency ablation

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=85041077690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041077690&partnerID=8YFLogxK

U2 - 10.1111/liv.13670

DO - 10.1111/liv.13670

M3 - Article

JO - Liver International

JF - Liver International

SN - 1478-3223

ER -